TMZ

Where’s Kate? Speculation about the ‘missing’ princess is proof the Palace’s media playbook needs a re-write

Retrieved on: 
Wednesday, March 13, 2024
Online, Sandringham, Associated Press, Social media, Reuters, AFP, Breeding, Catherine, Princess of Wales, Easter, Coma, News, Incest, English, Duke, Pleasure, TMZ, Nausea, Vomiting, Pregnancy, Hysterectomy, Getty Images, Health, Princess, Hyperemesis gravidarum, Kensington Palace, Death, Practice, Divorce, Child, Comment, Buckingham Palace, Cancer

Social media have been awash with speculation about Catherine’s health and whereabouts.

Key Points: 
  • Social media have been awash with speculation about Catherine’s health and whereabouts.
  • As scrutiny reaches a fever pitch, we ask: why is the Palace’s typical media playbook no longer working?

Not so ‘unprecedented’

  • Anne Boleyn (circa 1501-1536), the second of six wives of Henry VIII, was executed after being found guilty of adultery, incest and treason.
  • The long-reigning Queen Victoria (1819-1901) was widely regarded as as a loyal wife and mother.
  • Yet she too became the target of gossip regarding her close friendship with Scottish servant John Brown after her husband, Prince Albert, died in 1861.

The Palace’s strategic communications

  • The royal family has gradually adjusted to new media and technologies, though not as quickly as the public might like.
  • On one hand, the Palace continues its age-old tradition of announcing major news on a noticeboard at the gates of Buckingham Palace.

Internet sleuthing and a manipulated image

  • There were also more serious claims that she was in a coma, or dead, or getting a divorce.
  • In the midst of this speculation, TMZ published a grainy photo of Catherine in the passenger seat of a car near Windsor Castle.
  • The public quickly realised the image was at best poorly photoshopped or at worst AI-generated.
  • The Associated Press, Getty Images, AFP and Reuters subsequently issued “kill notices” on the image, stating concerns it had been digitally manipulated.

Old media PR won’t work in a new media world

  • The situation with Catherine’s absence from public life exposes the limits of old media strategies in a “new media” world.
  • The Palace is used to being able to control media coverage through the royal rota, a select group of press outlets in the UK given access to royal events.
  • Yet the interest in Catherine’s health has prompted a number of statements to the press.
  • These old media strategies don’t seem to be working, with news outlets that are part of the royal rota reporting critically on the manipulated image.


The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Pineapple Express Hollywood Dispensary Celebrates its 2-Year Anniversary Amidst Growing Pains

Retrieved on: 
Tuesday, February 20, 2024
LOS, Grammy Awards, OTC, TMZ, Pineapple Express, Pineapple, Hollywood and Vine, Partnership, Nightclub

LOS ANGELES, CA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pineapple Express Cannabis Company (OTC: PNXP) (the “Company” or “Pineapple Express”), a publicly traded company, today announced its 2-Year anniversary celebration of its flagship Pineapple Express Hollywood dispensary on the walk of fame in Hollywood, Ca., on the heels of resolving a partnership dispute.

Key Points: 
  • Dispensary’s 2nd anniversary celebration will be held at its flagship location at the iconic intersection of Hollywood & Vine, Saturday, February 24th from 12:00 to 4:00.
  • LOS ANGELES, CA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pineapple Express Cannabis Company (OTC: PNXP) (the “Company” or “Pineapple Express”), a publicly traded company, today announced its 2-Year anniversary celebration of its flagship Pineapple Express Hollywood dispensary on the walk of fame in Hollywood, Ca., on the heels of resolving a partnership dispute.
  • As reported by TMZ and other outlets, the investor star power at this location is impressive and includes a Grammy winning recording artist, an All-Pro retired football player, and well-known pop icons.
  • All have commemorative stars on the floor of the dispensary themed like the real walk of fame stars just steps away.

Mike Tyson recently launched a 6th to 12th grade Academy for students in Phoenix, Arizona

Retrieved on: 
Thursday, February 15, 2024
Multimedia, TTA, Education, TMZ, WWE, WWE Championship, Mixed martial arts, Student

PHOENIX, Feb. 15, 2024 /PRNewswire/ -- Tyson Transformational Technologies Academy's (Tyson's TTA) is a Cognia Accredited Micro-School in Arizona serving youth grades 6th to 12th grade. All tuition costs are covered through the Empowerment Scholarship Account (ESA Scholarship) and internal school scholarships. Tyson has generously given his name, likeness, time and talents to impact the lives of our future generations of youth in the Phoenix area with no compensation.

Key Points: 
  • PHOENIX, Feb. 15, 2024 /PRNewswire/ -- Tyson Transformational Technologies Academy's (Tyson's TTA) is a Cognia Accredited Micro-School in Arizona serving youth grades 6th to 12th grade.
  • Mike Tyson recently launched a 6th to 12th grade Academy for students in Phoenix, Arizona
    This marks a significant milestone in the world of education and philanthropy as Tyson's TTA is dedicated to emphasizing the importance and fostering the emotional, belief, and physiological intelligence.
  • It is a trailblazer in education that is committed to serving the diverse needs of middle and high school students.
  • The new educational institution, founded by Mike Tyson, aims to redefine learning by combining innovation, financial literacy, mentorship, and community engagement.

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Retrieved on: 
Wednesday, February 14, 2024
Glioblastoma, Neoplasm, PFS, Progression-free survival, Recurrence, Toxicity, Quality of life, TMZ, GBM, Cell, Safety, DDR, DRI, Patient, Brain, Survival, NKG2D, Temozolomide, DNA, Radiation, Vaccine

(NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach for solid tumors, such as glioblastoma (GBM), an aggressive form of brain cancer.

Key Points: 
  • (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach for solid tumors, such as glioblastoma (GBM), an aggressive form of brain cancer.
  • Cellular therapies, particularly chimeric antigen receptor T cell therapies (CAR-T), have shown promise in hematologic malignancies but have faced significant challenges when applied to solid tumors like GBM.
  • The INB-200 and INB-400 studies by IN8bio addresses the challenges towards targeting solid tumors by harnessing the innate immune functions of gamma-delta T cells.
  • IN8bio is also conducting a Phase 2 clinical trial of a genetically modified autologous gamma-delta T cell therapy (INB-400) targeting newly diagnosed GBM.

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

Retrieved on: 
Tuesday, January 9, 2024
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Quality of life, Temozolomide, Survival, Patient, GBM, Clinical trial, TMZ, Disease, Progression-free survival, Neoplasm, NANO, Glioblastoma, TRIDENT, Medical imaging

The TRIDENT study could unlock our ability to reach patients earlier in their treatment journey, further extending patient survival.

Key Points: 
  • The TRIDENT study could unlock our ability to reach patients earlier in their treatment journey, further extending patient survival.
  • The TRIDENT clinical trial is a randomized, open-label study designed to enroll 950 adult patients with newly diagnosed GBM.
  • Following maximal debulking surgery, patients enrolled in TRIDENT were randomized to receive either TTFields therapy, concomitant with TMZ and radiation therapy, or TMZ and radiation therapy for six weeks.
  • TRIDENT began enrolling patients in December 2020 and is the largest trial Novocure has conducted to date.

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Retrieved on: 
Sunday, November 19, 2023
Temozolomide, Safety, Glioblastoma, Dana–Farber Cancer Institute, GBM, Molecular medicine, Medicine, TMZ, Patient, Tokyo Stock Exchange, Immunohistochemistry, Neoplasm, Integrin alpha M, Harvard Medical School, Survival, CD74, Cleveland Clinic, Society, SNO, CD3, Standard Market Design, Life, Biopsy, Code, Pharmaceutical industry, Neurology

The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.

Key Points: 
  • The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.
  • MN-166 (ibudilast) and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported.
  • We are eager to evaluate MN-166 (ibudilast) in combination with anti-PD1 and anti-PD-L1 therapies in a future clinical trial.
  • MediciNova is grateful to the patients and families for their invaluable participation in our trial.”

BioMimetix Presents Data from Phase 2 Study of BMX-001 Demonstrating Increased Survival of 6.6 Months in High Grade Glioma Patients at the 2023 Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Friday, November 17, 2023
Oncology, Health, Neurology, Clinical Trials, Research, Science, Biotechnology, Temozolomide, Annual general meeting, Radiation, Porphyrin, Pakistan Society of Neuro-Oncology, HGG, Disease, Patient, TMZ, White matter, Neuro-Oncology (journal), Prognosis, Standard of care, MD, RT, Cancer, Survival, Toxic leukoencephalopathy, Growth, Neoplasm, Quality of life, SNO, Lead, Medical imaging, Cognition

“Patients with high grade glioma are challenging to treat because the disease grows quickly, ultimately outcomes are very poor for these patients and often carries an unfavorable prognosis.

Key Points: 
  • “Patients with high grade glioma are challenging to treat because the disease grows quickly, ultimately outcomes are very poor for these patients and often carries an unfavorable prognosis.
  • This is demonstrated by the promising effects seen in this trial with BMX-001 on patients with high grade glioma receiving concurrent radiation and chemotherapies,” said James Crapo, M.D., Chief Executive Officer at BioMimetix.
  • “High grade glioma is an aggressive brain cancer with a low survival rate that affects 10,000-15,000 people in the US per year.
  • Patients on concurrent RT/TMZ who also received BMX-001 were found to have an increased median survival of 6.6 months.

Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Friday, November 10, 2023
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Neurology, Other Science, Research, Science, Clinical Trials, CNS, Neoplasm, Vancouver Convention Centre, Safety, Annual general meeting, PST, Quality, Radiosurgery, Pakistan Society of Neuro-Oncology, Barrier, American Brain Tumor Association, TRIDENT, GBM, Chemoradiotherapy, Patient, TMZ, TTF, Radiation, Alternating electric field therapy, Quality of life, Lung cancer, Neuro, Biomarker, Trial of the century, METIS, Survival, TIGER, Central nervous system, Immunotherapy, Skin, Oligodendroglioma, SNO, NSCLC, Medical imaging, Pharmaceutical industry, Communications satellite, Glioblastoma

The 2023 SNO Annual Meeting will also mark the debut of Novocure’s new Optune Gio™ brand.

Key Points: 
  • The 2023 SNO Annual Meeting will also mark the debut of Novocure’s new Optune Gio™ brand.
  • Long-term global post-marketing surveillance data from pediatric, adult and elderly patients with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy.
  • 7:30 p.m. PST on Friday, Nov. 17
    Adopting Tumor Treating Fields (TTFields) therapy for glioblastoma and other solid cancers: challenges and opportunities.
  • 7:30 p.m. PST on Friday, Nov. 17
    Development of Tumor Treating Fields (TTFields) arrays for treatment of head tumors in mice models.

FreeCast Partners with StackComerce to Distribute Value Channels

Retrieved on: 
Thursday, December 7, 2023
Mashable, CNET, TMZ, Multimedia, Pursuit Channel, Sony Movies, Partnership, PCMag, TechCrunch, IGN, Online shopping, Entrepreneurship, FreeCast, Engadget

ORLANDO, Fla., Dec. 7, 2023 /PRNewswire/ -- FreeCast is announcing a marketing agreement with StackCommerce to promote its Value Channels virtual pay-TV package. Value Channels includes popular pay channels, seamlessly integrating them into FreeCast's SmartGuide, alongside other free streaming channels and the entire universe of on-demand video. StackCommerce will promote this package via its own partnerships with hundreds of online brands and publishers, making special pricing available to millions of potential customers.

Key Points: 
  • ORLANDO, Fla., Dec. 7, 2023 /PRNewswire/ -- FreeCast is announcing a marketing agreement with StackCommerce to promote its Value Channels virtual pay-TV package.
  • Value Channels includes popular pay channels, seamlessly integrating them into FreeCast's SmartGuide, alongside other free streaming channels and the entire universe of on-demand video.
  • Value Channels is a bundle of 20 cable channels that can be added on to FreeCast's service, including popular networks like the Curiosity Channel, Sony Movies, the Pursuit Channel, and REELZ, home of the hit show On Patrol: Live.
  • FreeCast CEO William Mobley discussed the value of StackCommerce' reach: "This partnership is a great fit.

MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO

Retrieved on: 
Tuesday, November 7, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Survival, Research, Research and development, Trial of the century, IND, NYSE, Food, DCR, Enrollment, Form, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, CPI, Investigational New Drug, DCR Workforce, Diffuse intrinsic pontine glioma, Cancer, Central nervous system, Lung cancer, TMZ, Patient, Drug discovery, Potential, Administration, DIPG, Pharmaceutical industry, Mobile phone, Medical imaging, Cryptocurrency, NSCLC, Glioma

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, today reported financial results for the third quarter ended September 30, 2023 and key operational updates.

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, today reported financial results for the third quarter ended September 30, 2023 and key operational updates.
  • Research and Development (R&D) Expenses: R&D expenses were approximately $2.6 million for the quarter ended September 30, 2023, compared to approximately $2.3 million for quarter ended September 30, 2022.
  • Weighted average shares outstanding were 13,675,802 in the third quarter of 2023, compared to 10,165,622 in the third quarter of 2022.
  • For additional information on the Company’s financial results for the quarter ended September 30, 2023, please refer to the Form 10-Q filed with the SEC.